Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

A Phase I, Open-Label, Single-Dose Study of MP-424 in Patients With Genotype 1b Hepatitis C

The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.

Inclusion Criteria:

• Patients diagnosed with genotype 1b chronic hepatitis C
• Patients naive to the concomitant medications with interferon

Exclusion Criteria:

• Patients diagnosed with decompensated cirrhosis
• Patients diagnosed with positive HBs(Hepatitis B virus surface) antigen in the test